Drug profile · INN
sparsentan
FILSPARI
sparsentan (FILSPARI) is a type-1 angiotensin ii receptor antagonist. Associated with Travere Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Drug details — sparsentan
- US status
- approved
- Class
- Cardiovascular system (C09)
- Route
- ORAL
- Patents
- 1
- Programs
- 10
- Data quality
- 0.89
Quick answer
sparsentan (FILSPARI) is a type-1 angiotensin ii receptor antagonist. Associated with Travere Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Endothelin-1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is sparsentan?
sparsentan (FILSPARI) is a type-1 angiotensin ii receptor antagonist. Associated with Travere Therapeutics. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sparsentan?
FILSPARI is a marketed brand name for sparsentan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sparsentan?
sparsentan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.